SORT1 and breast carcinoma: Although 8D302-MMAE showed higher anti-tumor activity in vitro and in vivo, the better safety profile of 8D302-DXd may enable it to be a promising therapeutic agent for the treatment of patients with solid cancers, especially breast cancers with SORT1-high expression.